Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Frequently asked questions
What sector does Addex Therapeutics Ltd (ADXN) operate in?
Addex Therapeutics Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Addex Therapeutics Ltd (ADXN) current stock price?
As of the latest data, Addex Therapeutics Ltd stock price is CHF 0.04, with a previous close of CHF 0.04.
What is Addex Therapeutics Ltd (ADXN) current market capitalization?
Addex Therapeutics Ltd market cap is approximately 6.14 million.
What is Addex Therapeutics Ltd (ADXN) Earnings Per Share (EPS)?
The trailing EPS is -CHF 0.06, and the forward EPS is -CHF 0.04.
What is Addex Therapeutics Ltd (ADXN) EBITDA?
Addex Therapeutics Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -470.01 thousand.
Does Addex Therapeutics Ltd (ADXN) pay dividends?
No. Addex Therapeutics Ltd does not pay a dividend.
When is Addex Therapeutics Ltd (ADXN) next earnings report?
Addex Therapeutics Ltd is expected to release its next earnings report on June 30, 2026.
What is Addex Therapeutics Ltd (ADXN) beta (volatility) score?
Addex Therapeutics Ltd has a beta of 1.994, suggesting it is more volatile than the market.
